Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
Company Contact | |
Address: | 700 Collip Circle, Ste 114 LONDON ON N6G 4X8 |
Tel: | 1-519-9027923 |
Website: | https://www.sernova.com |
IR: | See website |
Key People | ||
Brett Whalen Chairman of the Board | Cynthia Pussinen Chief Executive Officer, Director | David C. Swetlow Chief Financial Officer |
Philip M. Toleikis Chief Technology Officer | Chris Barnes Vice President of Investor Relations | Frank Shannon Vice President - Clinical Development and Regulatory Affairs | Modestus Obochi Chief Business Officer |
Business Overview |
Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases. |
Financial Overview |
For the three months ended 31 January 2024, Sernova Corp revenues was not reported. Net loss increased 22% to C$9.7M. Higher net loss reflects Consulting and professional fees increase from C$162K to C$692K (expense), Personnel costs increase of 56% to C$865K (expense), Interest income decrease of 64% to C$166K (income). Basic Earnings per Share excluding Extraordinary Items remained flat at -C$0.03. |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $121.84M as of Jan 31, 2024 |
Annual revenue (TTM): | $0.00M as of Jan 31, 2024 |
EBITDA (TTM): | -$41.48M as of Jan 31, 2024 |
Net annual income (TTM): | -$40.73M as of Jan 31, 2024 |
Free cash flow (TTM): | -$29.14M as of Jan 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 303,407,686 as of Mar 13, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |